
Join to view full profile
1583 Health Care DrRock Hill, SC 29732
Phone+1 803-329-7772
Fax+1 803-329-9821
Dr. Patel is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Kashyap Patel is the CEO of Carolina Blood and Cancer Care Associates. Dr. Patel is a practicing medical oncologist, board certified in Hematology, Oncology, and Internal Medicine. He is immediate past president for the Community Oncology Alliance (COA), He is past for the clinical affairs and trustee for the Association of Community Cancer Centers (ACCC). He has published/presented over 130 papers. He is frequently interviewed and cited in mainstream newspapers including NY times, Washington Post, NPR just to name a few including on key issues like Covid 19, Healthcare disparities, value-based care. He is also frequenly invited by WH team to opine of Cancer Moonshot program
He has been an advisor for the large payers including DHHS (SC), Palmetto GBA, and serves on an advisory board for Medicaid HMOs. He has a special interest in health care policy and economics, and he has expertise in Value Based Care and has successfully led Oncology Care Model pilots with two payers including with CMMI
Additionally, Dr Patel has been working directly with cancer patients for the last twenty years. He has served as chairman of several committees in numerous South Carolina hospitals. Moreover, he has extensive research experience in oncology. Dr. Patel has extensive legislative experience both at the local and national level. He has testified in state senate as well as has carried out capitol hill briefing on precision medicine.
He has been honored by the US Congress for his exceptional contribution to the healthcare. Multiple journals have written about his life. He is now working with multiple national entities on cancer health disparities
Education & Training
University of FloridaResidency, Gastroenterology, 2016 - 2022
Sidney Kimmel Medical College at Thomas Jefferson University/TJUHFellowship, Hematology and Medical Oncology, 1999 - 2002
Jamaica Hospital Medical CenterResidency, Internal Medicine, 1996 - 1999
N.H.L Municipal Medical CollegeClass of 1984
Certifications & Licensure
NC State Medical License 2003 - 2027
SC State Medical License 2002 - 2027
NY State Medical License 1999 - 2018
FL State Medical License 2002 - 2006
PA State Medical License 1999 - 2006
NJ State Medical License 2000 - 2005
MI State Medical License 1999 - 2000
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification Agastha Enterprise Healthcare Software, Agastha, Inc., 2011, 2013, 2015-2017
- CMS Meaningful Use Stage 1 Certification Agastha Enterprise Healthcare Software, Agastha, Inc., 2011, 2013, 2015-2017
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2011
Publications & Presentations
PubMed
- 1 citations340B Drug Pricing Program: An Updated ASCO Policy Statement.Blase Polite, Niharika Dixit, John Hennessy, Marissa Rivera, Ashley Sumrall
JCO Oncology Practice. 2026-09-01 - 2 citationsMedically Integrated Dispensing Pharmacy: ASCO-Network for Collaborative Oncology Development & Advancement Standards Update.Luis E Raez, Xylina T Gregg, Gurjyot K Doshi, Scott Freeswick, Austin Cox
JCO Oncology Practice. 2025-11-01 - 1 citationsClinical Utility of the EpiSwitch CiRT Test to Guide Immunotherapy Across Solid Tumors: Interim Results from the PROWES Study.Joe Abdo, Joos Berghausen, Ryan Mathis, Thomas Guiel, Ewan Hunter
Cancers. 2025-09-04
Press Mentions
Oxford Biodynamics to Present on Its Line of EpiSwitch® Products for Companion Diagnostics in Cancer Immunotherapy at the 14th World Summit for Clinical Biomarkers and Companion Diagnostics in Boston, MAJuly 25th, 2024
Covid Might Be to Blame for an Uptick in Rare CancersJune 20th, 2024
Rare and ‘Unusual’ Cancers Are Emerging After the Covid Pandemic – and Doctors Fear an Unlikely Culprit Is to BlameJune 7th, 2024
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: